CLINICAL TRIALS PROFILE FOR ERITORAN
✉ Email this page to a colleague
Clinical Trials for Eritoran
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00334828 ↗ | ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis | Completed | Eisai Inc. | Phase 3 | The purpose of this study is to compare eritoran tetrasodium and placebo in patients with severe sepsis and to demonstrate a reduction of mortality from all causes. |
| NCT00756912 ↗ | A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors | Terminated | Eisai Inc. | Phase 1 | This is a study designed to assess the safety of administration of up to 3 dose levels of eritoran in subjects undergoing or scheduled to undergo allogeneic bone marrow transplant (BMT). An allogeneic BMT is the transplantation of blood stem cells taken from the bone marrow or blood of another person. |
| NCT02267317 ↗ | The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects | Terminated | Nicolas Musi | Phase 2 | To determine whether pharmacologic inhibition of Toll-like receptor 4 (TLR4) with eritoran for injection (E5564) will reduce inflammation and improve glucose metabolism in insulin resistant (obese and T2DM) subjects. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Eritoran
Condition Name
Clinical Trial Locations for Eritoran
Trials by Country
Clinical Trial Progress for Eritoran
Clinical Trial Phase
Clinical Trial Sponsors for Eritoran
Sponsor Name
